Puma Biotechnology reported a slight increase in net NERLYNX revenue to $48.9 million in Q2 2021 from $48.8 million in Q2 2020. The company reported a net loss of $5.1 million, or $0.13 per share, compared to a net income of $3.4 million, or $0.09 per share, for the same period in the previous year. Non-GAAP adjusted net income was $13.1 million, or $0.32 per share, compared to $14.0 million, or $0.36 per share, for the second quarter of 2020. Cash, cash equivalents and marketable securities totaled $108.9 million as of June 30, 2021.
Net NERLYNX revenue for Q2 2021 was $48.9 million, a slight increase from $48.8 million in Q2 2020.
Puma reported a net loss of $5.1 million, or $0.13 per share, for Q2 2021, compared to a net income of $3.4 million, or $0.09 per share, for Q2 2020.
Non-GAAP adjusted net income for Q2 2021 was $13.1 million, or $0.32 per share, compared to $14.0 million, or $0.36 per share, for Q2 2020.
Cash, cash equivalents and marketable securities totaled $108.9 million as of June 30, 2021, compared to $93.4 million at December 31, 2020.
Puma Biotechnology anticipates several key milestones over the next 12 months.
Analyze how earnings announcements historically affect stock price performance